Fig. 6: Association of mtDNA-based tumor evolutionary score (MTES) with therapeutic efficacy in ovarian cancer. | Experimental & Molecular Medicine

Fig. 6: Association of mtDNA-based tumor evolutionary score (MTES) with therapeutic efficacy in ovarian cancer.

From: Metastatic pattern of ovarian cancer delineated by tracing the evolution of mitochondrial DNA mutations

Fig. 6: Association of mtDNA-based tumor evolutionary score (MTES) with therapeutic efficacy in ovarian cancer.The alternative text for this image may have been generated using AI.

a MTES for all patients, sorted in ascending order (from low to high). The patients were divided into high MTES (red) and low MTES (blue) groups based on the median value. The arrow indicates the representative cases shown in Fig. 5 (patient 3 and patient 27). b Time course change in CA125 values in the two groups before and after surgery and during six courses of adjuvant chemotherapy. The normal CA125 value is less than 22.5 U/L, marked by dashed lines. c Proportion of patients with normal CA125 values in the two groups after surgery and chemotherapy treatment. d CA125 remission rate after surgery (left panel) and after surgery and adjuvant chemotherapy (right panel) in the two groups. The CA125 remission rate was calculated as the ratio of the decreased CA125 level after treatment to the CA125 level before treatment. e Comparison of CA125 variation during six courses of adjuvant chemotherapy in the two groups. The variation was measured by the standard deviation (SD) of the CA125 level during chemotherapy.

Back to article page